GO:0046525 xylosylprotein 4-beta-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046525 (xylosylprotein 4-beta-galactosyltransferase activity) catalyzes the transfer of galactose from UDP-galactose to O-beta-D-xylosylprotein, forming the second sugar of the glycosaminoglycan-protein linkage region.
• The human enzyme responsible is beta-1,4-galactosyltransferase 7 (B4GALT7), also known as galactosyltransferase I.
• Mutations in B4GALT7 cause the progeroid variant of Ehlers-Danlos syndrome, a connective tissue disorder.
• The Drosophila homolog is essential for glycosaminoglycan synthesis and morphogenesis.
• Key active-site residues of human B4GALT7 have been mapped, including those involved in UDP-galactose binding and catalysis.
• The enzyme is a validated target for biochemical assays and structural studies, with recombinant production methods available.
Description
Xylosylprotein 4-beta-galactosyltransferase activity (GO:0046525) is a molecular function that catalyzes the second step in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. This reaction transfers galactose from UDP-galactose to O-beta-D-xylosylprotein, producing 4-beta-D-galactosyl-O-beta-D-xylosylprotein and UDP. The enzyme responsible in humans is beta-1,4-galactosyltransferase 7 (B4GALT7), also called galactosyltransferase I. This activity is critical for the assembly of chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin, which are essential components of the extracellular matrix and cell surface. Researchers study GO:0046525 to understand connective tissue disorders, developmental processes, and glycosaminoglycan-related pathologies.
xylosylprotein 4-beta-galactosyltransferase activity At A Glance
| GO ID | GO:0046525 |
|---|---|
| GO term | xylosylprotein 4-beta-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | galactosyltransferase I activity; UDP-D-galactose:D-xylose galactosyltransferase activity; UDP-galactose:O-beta-D-xylosylprotein 4-beta-D-galactosyltransferase activity |
| Major function | Transfer of galactose from UDP-galactose to O-beta-D-xylosylprotein, forming the second sugar of the glycosaminoglycan-protein linkage region |
| Enzyme commission | EC 2.4.1.133 |
| Human gene | B4GALT7 (beta-1,4-galactosyltransferase 7) |
| Disease association | Progeroid variant of Ehlers-Danlos syndrome (mutations in B4GALT7) |
| Subcellular location | Golgi apparatus (as a type II membrane protein) |
What Is GO:0046525?
According to the Gene Ontology, GO:0046525 is defined as the catalysis of the reaction: UDP-galactose + O-beta-D-xylosylprotein = UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein. In other words, it is the enzymatic activity that adds a galactose residue in a beta-1,4 linkage to a xylose molecule that is already attached to a protein, forming the second sugar of the tetrasaccharide linkage region that connects glycosaminoglycan chains to core proteins.
Why Is xylosylprotein 4-beta-galactosyltransferase activity Important in Cell Biology?
GO:0046525 is essential for the biosynthesis of proteoglycans, which are key components of the extracellular matrix and cell surface. The reaction it catalyzes is the second step in the formation of the glycosaminoglycan-protein linkage region, a tetrasaccharide that serves as the attachment point for glycosaminoglycan chains such as chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin. Defects in this activity lead to connective tissue disorders, as evidenced by mutations in B4GALT7 causing the progeroid variant of Ehlers-Danlos syndrome. In Drosophila, the homolog is required for glycosaminoglycan synthesis and morphogenesis. Thus, understanding this enzyme is important for developmental biology, matrix biology, and disease research.
• Required for the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans.
• Mutations in the human gene B4GALT7 cause the progeroid variant of Ehlers-Danlos syndrome.
• Essential for glycosaminoglycan synthesis and morphogenesis in Drosophila.
• Plays a role in extracellular matrix assembly and cell signaling.
• Target for biochemical assays to measure galactosyltransferase I activity.
• Recombinant production enables structural and functional studies.
• Key active-site residues have been identified, aiding inhibitor design.
• Involved in connective tissue integrity and development.
Molecular Mechanism of xylosylprotein 4-beta-galactosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs the sugar donor and the acceptor molecule.
The enzyme binds UDP-galactose as the donor substrate and O-beta-D-xylosylprotein as the acceptor. Key residues in the active site of human B4GALT7 are involved in binding the UDP-galactose and the xylose moiety. The acceptor is a xylose residue that has been transferred to a specific serine residue on the core protein by xylosyltransferase.
Catalytic Transfer of Galactose
In simple terms: The enzyme moves galactose from UDP-galactose onto the xylose sugar.
The catalytic mechanism involves the transfer of galactose from UDP-galactose to the 4-hydroxyl group of the xylose residue, forming a beta-1,4 linkage. This reaction produces UDP and 4-beta-D-galactosyl-O-beta-D-xylosylprotein. The enzyme is a retaining glycosyltransferase, though the exact mechanism may involve a double displacement or a SNi-like mechanism.
Role in Glycosaminoglycan Linkage Region Assembly
In simple terms: This step builds the second sugar of the linker that attaches long sugar chains to proteins.
The product of this reaction, galactosyl-xylosyl-protein, is the substrate for the next enzyme, galactosyltransferase II (B3GALT6), which adds galactose in a beta-1,3 linkage. Further addition of glucuronic acid and another galactose completes the tetrasaccharide linkage region, after which glycosaminoglycan chains are polymerized. Thus, GO:0046525 is a critical early step in proteoglycan biosynthesis.
Enzyme Structure and Active Site
In simple terms: The enzyme has a specific pocket where the reaction happens.
Human B4GALT7 is a type II membrane protein localized to the Golgi apparatus. The active site contains conserved residues that coordinate the UDP-galactose and the acceptor. Mutagenesis studies have identified key functional residues, including those that affect substrate binding and catalysis. The enzyme can be produced recombinantly in E. coli as a soluble, folded protein using fusion partners such as galectin-1.
Regulation and Cofactors
In simple terms: The enzyme does not need metal ions but is regulated by substrate availability.
The enzyme requires no metal ion cofactors; it uses UDP-galactose as both sugar donor and energy source. Its activity can be regulated by the availability of UDP-galactose and the acceptor substrate. The enzyme is also subject to feedback inhibition by its product, UDP. In addition, expression levels of B4GALT7 may be regulated during development and in disease states.
Key Genes Involved in GO:0046525 xylosylprotein 4-beta-galactosyltransferase activity
The following genes and proteins are directly involved in or regulate xylosylprotein 4-beta-galactosyltransferase activity (GO:0046525).
| Gene | Major Role | Research Relevance |
|---|---|---|
| B4GALT7 | Encodes galactosyltransferase I, the enzyme that catalyzes GO:0046525 | Mutations cause progeroid Ehlers-Danlos syndrome; target for structural and functional studies |
| XYLT1 | Xylosyltransferase 1, adds xylose to serine residues of core proteins, creating the acceptor for B4GALT7 | Defects cause Desbuquois dysplasia; upstream of GO:0046525 |
| XYLT2 | Xylosyltransferase 2, similar to XYLT1, initiates linkage region | Defects cause spondyloocular syndrome; upstream of GO:0046525 |
| B3GALT6 | Galactosyltransferase II, adds galactose in beta-1,3 linkage after B4GALT7 | Mutations cause Ehlers-Danlos syndrome, spondyloepimetaphyseal dysplasia; downstream of GO:0046525 |
| B3GAT3 | Glucuronyltransferase I, adds glucuronic acid to the linkage region | Mutations cause connective tissue disorders; downstream of GO:0046525 |
| B4GALT1 | Beta-1,4-galactosyltransferase 1, involved in N-glycan and O-glycan synthesis, not directly in GO:0046525 but related | Studied for sperm acrosome reaction; not the same enzyme |
| B4GALT2 | Beta-1,4-galactosyltransferase 2, similar to B4GALT1, not directly GO:0046525 | Potential redundancy in galactosylation |
| B4GALT3 | Beta-1,4-galactosyltransferase 3, not directly GO:0046525 | Related family member |
| B4GALT4 | Beta-1,4-galactosyltransferase 4, not directly GO:0046525 | Related family member |
| B4GALT5 | Beta-1,4-galactosyltransferase 5, not directly GO:0046525 | Related family member |
| B4GALT6 | Beta-1,4-galactosyltransferase 6, not directly GO:0046525 | Related family member |
| SLC35B4 | UDP-galactose transporter, supplies substrate for GO:0046525 | Indirect role in glycosaminoglycan synthesis |
| SLC35A2 | UDP-galactose transporter, supplies substrate | Indirect role |
| SLC35A3 | UDP-GlcNAc transporter, not directly related | Indirect role |
| EXT1 | Heparan sulfate polymerase, acts after linkage region is formed | Downstream of GO:0046525 |
| EXT2 | Heparan sulfate polymerase, acts after linkage region | Downstream of GO:0046525 |
| CHSY1 | Chondroitin sulfate synthase, acts after linkage region | Downstream of GO:0046525 |
| CSGALNACT1 | Chondroitin sulfate N-acetylgalactosaminyltransferase 1, acts after linkage region | Downstream of GO:0046525 |
How Is xylosylprotein 4-beta-galactosyltransferase activity Regulated?
The activity of xylosylprotein 4-beta-galactosyltransferase is primarily regulated by the availability of its substrates, UDP-galactose and O-beta-D-xylosylprotein. The enzyme is localized to the Golgi apparatus, where it encounters its substrates. Expression of B4GALT7 may be regulated during development, as suggested by its essential role in Drosophila morphogenesis. In humans, mutations in B4GALT7 reduce or abolish enzyme activity, leading to disease. No specific allosteric regulators or post-translational modifications have been extensively characterized, but the enzyme is subject to product inhibition by UDP.
xylosylprotein 4-beta-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B4GALT7 | Progeroid variant of Ehlers-Danlos syndrome | Patient-derived fibroblasts, CRISPR knock-in of patient mutations in HEK293 or iPSCs |
| B4GALT7 | Defective glycosaminoglycan synthesis | Knockout cell lines (e.g., HEK293, CHO) and measurement of linkage region intermediates |
| XYLT1 | Desbuquois dysplasia (upstream of GO:0046525) | Knockout zebrafish or mouse models |
| B3GALT6 | Ehlers-Danlos syndrome, spondyloepimetaphyseal dysplasia (downstream of GO:0046525) | CRISPR knock-in of patient mutations in cell lines |
| B4GALT7 (Drosophila homolog) | Morphogenesis defects | Drosophila melanogaster mutants |
Progeroid Variant of Ehlers-Danlos Syndrome
Mutations in B4GALT7, the gene encoding galactosyltransferase I, cause the progeroid variant of Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by aged appearance, skin hyperextensibility, joint hypermobility, and skeletal abnormalities. This disease highlights the critical role of GO:0046525 in maintaining extracellular matrix integrity.
Developmental Disorders
In Drosophila, mutations in the homolog of B4GALT7 result in defective glycosaminoglycan synthesis and abnormal morphogenesis, demonstrating the importance of this activity in development. In humans, defects in glycosaminoglycan synthesis can lead to a spectrum of skeletal and connective tissue disorders.
Cancer and Metastasis
Altered glycosaminoglycan biosynthesis, including changes in the linkage region, has been implicated in cancer progression and metastasis, though direct evidence for GO:0046525 in cancer is limited. Further research is needed to establish a causal role.
From xylosylprotein 4-beta-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of B4GALT7 loss on glycosaminoglycan synthesis? | CRISPR knockout of B4GALT7 in HEK293 or CHO cells, followed by linkage region analysis |
| How do disease-causing mutations affect enzyme activity? | Point mutations (e.g., A186D, R270C) introduced by CRISPR knock-in into endogenous B4GALT7 locus |
| Can we rescue the defect by expressing wild-type enzyme? | Knock-in of tagged B4GALT7 (e.g., FLAG) for localization and rescue experiments |
| What is the subcellular localization of B4GALT7? | Tagged knock-in of B4GALT7 with fluorescent protein in HeLa or COS-7 cells |
| Does overexpression of B4GALT7 increase glycosaminoglycan production? | Overexpression of B4GALT7 in CHO cells or fibroblasts, followed by glycosaminoglycan quantification |
| Can we identify small molecule inhibitors of B4GALT7? | High-throughput screening using recombinant B4GALT7 and a fluorescent acceptor |
How to Study the xylosylprotein 4-beta-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiochemical assay with UDP-[3H]galactose | Galactosyltransferase I activity | Enzyme kinetics and inhibitor screening |
| Mass spectrometry | Linkage region intermediates and products | Characterization of glycosaminoglycan synthesis defects |
| CRISPR-Cas9 knockout | Loss-of-function phenotypes | Studying the role of B4GALT7 in cells |
| CRISPR-Cas9 knock-in | Expression of mutant or tagged protein | Modeling patient mutations or localization studies |
| Recombinant expression in E. coli | Production of soluble enzyme | Structural and biochemical studies |
| Site-directed mutagenesis | Identification of key active-site residues | Mapping catalytic mechanism |
| Flow cytometry | Cell surface glycosaminoglycan levels | Phenotypic analysis of knockout cells |
| Immunofluorescence | Subcellular localization | Determining Golgi localization of B4GALT7 |
Enzymatic Activity Assays
Galactosyltransferase I activity can be measured using a radiochemical assay with UDP-[3H]galactose and a xylose-containing acceptor, followed by product separation. Alternatively, fluorescent or mass spectrometry-based methods can be used.
Glycosaminoglycan Analysis
The products of GO:0046525 can be analyzed by HPLC, mass spectrometry, or gel electrophoresis after enzymatic digestion of proteoglycans. Linkage region tetrasaccharides can be released by beta-elimination and characterized.
CRISPR-Cas9 Genome Editing
Knockout, knock-in, and point mutations can be introduced into B4GALT7 or related genes using CRISPR-Cas9 to study the effects on glycosaminoglycan synthesis and cellular phenotypes.
Recombinant Protein Production
Soluble B4GALT7 can be produced in E. coli using fusion partners such as galectin-1, enabling structural and biochemical studies.
How CRISPR Can Be Used to Study GO:0046525 xylosylprotein 4-beta-galactosyltransferase activity
Knockout
CRISPR-Cas9 knockout of B4GALT7 in cell lines such as HEK293 or CHO can abolish GO:0046525 activity, leading to defective glycosaminoglycan synthesis and accumulation of xylosylprotein intermediates. These models are useful for studying the consequences of loss of function and for testing rescue constructs.
Point Mutation
Point mutations identified in patients with Ehlers-Danlos syndrome (e.g., A186D, R270C) can be introduced into the endogenous B4GALT7 locus using CRISPR-Cas9 homology-directed repair. These models help determine how specific mutations affect enzyme activity and protein stability.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the B4GALT7 locus allows for tracking of the enzyme's localization and interaction partners. This approach can also be used to express wild-type enzyme under its endogenous promoter for rescue experiments.
Overexpression
Overexpression of B4GALT7 using CRISPR activation or lentiviral vectors can increase GO:0046525 activity, potentially enhancing glycosaminoglycan production. This is useful for biotechnological applications and for studying the effects of increased enzyme levels.
How EDITGENE Supports xylosylprotein 4-beta-galactosyltransferase activity Research
Researchers studying xylosylprotein 4-beta-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosaminoglycan synthesis, connective tissue integrity, or disease. EDITGENE provides comprehensive CRISPR-based services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for xylosylprotein 4-beta-galactosyltransferase activity research.
Frequently Asked Questions About xylosylprotein 4-beta-galactosyltransferase activity
What is xylosylprotein 4-beta-galactosyltransferase activity?
It is the enzymatic activity (GO:0046525) that transfers galactose from UDP-galactose to O-beta-D-xylosylprotein, forming the second sugar of the glycosaminoglycan-protein linkage region.
What genes are involved in xylosylprotein 4-beta-galactosyltransferase activity?
The primary gene is B4GALT7, which encodes galactosyltransferase I. Other genes in the pathway include XYLT1, XYLT2, B3GALT6, and B3GAT3.
What diseases are associated with mutations in B4GALT7?
Mutations in B4GALT7 cause the progeroid variant of Ehlers-Danlos syndrome, a connective tissue disorder.
How is xylosylprotein 4-beta-galactosyltransferase activity measured?
It can be measured using radiochemical assays with UDP-[3H]galactose and a xylose acceptor, or by mass spectrometry of the reaction products.
What is the role of B4GALT7 in glycosaminoglycan synthesis?
B4GALT7 catalyzes the second step in the formation of the glycosaminoglycan-protein linkage region, adding galactose to xylose.
Is xylosylprotein 4-beta-galactosyltransferase activity conserved in Drosophila?
Yes, a Drosophila homolog exists and is essential for glycosaminoglycan synthesis and morphogenesis.
What are the substrates of xylosylprotein 4-beta-galactosyltransferase?
The substrates are UDP-galactose and O-beta-D-xylosylprotein.
What are the products of the reaction catalyzed by GO:0046525?
The products are UDP and 4-beta-D-galactosyl-O-beta-D-xylosylprotein.
Can CRISPR be used to study xylosylprotein 4-beta-galactosyltransferase activity?
Yes, CRISPR-Cas9 can create knockouts, point mutations, and knock-ins in B4GALT7 to study its function and disease relevance.
What is the subcellular localization of B4GALT7?
B4GALT7 is a type II membrane protein localized to the Golgi apparatus.
Conclusion
Xylosylprotein 4-beta-galactosyltransferase activity (GO:0046525) is a critical enzymatic step in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. The human enzyme B4GALT7 is essential for connective tissue integrity, and its mutations cause the progeroid variant of Ehlers-Danlos syndrome. Studying this activity provides insights into extracellular matrix biology, development, and disease. EDITGENE offers a suite of CRISPR services to facilitate research on this important molecular function.
References
- 1. García-García JF et al.. 2011. Synthesis and evaluation of xylopyranoside derivatives as "decoy acceptors" of human β-1,4-galactosyltransferase 7.. Mol Biosyst 7(4):1312-21 PMID: 21327212
- 2. Nakamura Y et al.. 2002. Identification of a Drosophila gene encoding xylosylprotein beta4-galactosyltransferase that is essential for the synthesis of glycosaminoglycans and for morphogenesis.. J Biol Chem 277(48):46280-8 PMID: 12215432
- 3. Okajima T et al.. 1999. Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans.. J Biol Chem 274(33):22915-8 PMID: 10438455
- 4. Macek MB et al.. 1991. Aggregation of beta-1,4-galactosyltransferase on mouse sperm induces the acrosome reaction.. Dev Biol 147(2):440-4 PMID: 1916017
- 5. Furukawa K et al.. 2002. Galactosyltransferase I is a gene responsible for progeroid variant of Ehlers-Danlos syndrome: molecular cloning and identification of mutations.. Biochim Biophys Acta 1573(3):377-81 PMID: 12417421
- 6. Talhaoui I et al.. 2010. Identification of key functional residues in the active site of human {beta}1,4-galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway.. J Biol Chem 285(48):37342-58 PMID: 20843813
- 7. Higuchi T et al.. 1994. A method for determination of galactosyltransferase I activity synthesizing the proteoglycan linkage region.. J Biochem Biophys Methods 29(2):135-42 PMID: 7836658
- 8. Pasek M et al.. 2010. Galectin-1 as a fusion partner for the production of soluble and folded human beta-1,4-galactosyltransferase-T7 in E. coli.. Biochem Biophys Res Commun 394(3):679-84 PMID: 20226765
